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Abstract
Sophora flavescens is a Chinese medicinal herb used for the treatment of gastrointestinal hemorrhage, skin diseases, pyretic
stranguria and viral hepatitis. In this study the herb-drug interactions between S. flavescens and indinavir, a protease
inhibitor for HIV treatment, were evaluated in rats. Concomitant oral administration of Sophora extract (0.158 g/kg or
0.63 g/kg, p.o.) and indinavir (40 mg/kg, p.o.) in rats twice a day for 7 days resulted in a dose-dependent decrease of plasma
indinavir concentrations, with 55%–83% decrease in AUC0-‘ and 38%–78% reduction in Cmax. The CL (Clearance)/F (fraction
of dose available in the systemic circulation) increased up to 7.4-fold in Sophora-treated rats. Oxymatrine treatment (45 mg/
kg, p.o.) also decreased indinavir concentrations, while the ethyl acetate fraction of Sophora extract had no effect. Urinary
indinavir (24-h) was reduced, while the fraction of indinavir in faeces was increased after Sophora treatment. Compared to
the controls, multiple dosing of Sophora extract elevated both mRNA and protein levels of P-gp in the small intestine and
liver. In addition, Sophora treatment increased intestinal and hepatic mRNA expression of CYP3A1, but had less effect on
CYP3A2 expression. Although protein levels of CYP3A1 and CYP3A2 were not altered by Sophora treatment, hepatic CYP3A
activity increased in the Sophora-treated rats. All available data demonstrated that Sophora flavescens reduced plasma
indinavir concentration after multiple concomitant doses, possibly through hepatic CYP3A activity and induction of
intestinal and hepatic P-gp. The animal study would be useful for predicting potential interactions between natural
products and oral pharmaceutics and understanding the mechanisms prior to human studies. Results in the current study
suggest that patients using indinavir might be cautioned in the use of S. flavescens extract or Sophora-derived products.
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Introduction
Dried root of Sophora flavescens Ait. (Fabaceae), known in Chinese
as Ku-Shen, is widely used in traditional Chinese Medicine as a
‘‘cooling’’ drug for the treatment of gastrointestinal hemorrhage,
skin diseases, and pyretic stranguria. The herb is an antipyretic,
anthelminitic and diuretic agent [1]. Phytochemical studies have
revealed the presence of quinolizidine alkaloids and prenylated
flavonoids [2,3], both of which show a wide spectrum of phar-
macological activities, such as antitumor, cardioprotective, and
neuroprotective effects [4–6]. The alkaloids, such as matrine and
oxymatrine, are frequently used as the chemical markers for the
quality control of this medicinal herb. Pharmaceutical products
derived from these alkaloids, such as the Marine Capsule [Jiangsu
Chia-Tai Tianqing Pharmacy Co., China] (which contains mainly
oxymatrine and will be referred to as ‘‘oxymatrine capsule’’
thereafter),areavailableforthetreatmentofviralhepatitisinChina.
The widespread use of S. flavescens as complementary or
alternative medicine has led to increasing concerns on potential
herb-drug interactions through effects on enzyme pathways. It is
known that Cytochrome P450 (CYP)-dependent monooxygenase
system plays a primary role in the elimination of a variety of
xenobiotics and is often a major component of drug-drug and
herb-drug interactions. Sophora treatment has been shown to cause
CYP1A induction and male-specific induction of CYP2A and
CYP3A in mice, and it has been suggested that oxymatrine
contributed at least partly to the CYP induction by S. flavescens [7].
A further study demonstrated that S. flavescens reduced theophyl-
line plasma levels, which may be related to the inductions of
CYP1A2, CYP2B1/2, CYP2C11, and CYP3A [8]. Matrine and
oxymatrine, the two major pharmacologically active ingredients,
have been shown to cause CYP2B induction but not CYP3A,
possibly mediated by the activation of constitute androstane
receptor (CAR) [9]. More recently, a mechanistic study using cell-
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CYP3A expression through the activation of pregnane X receptor
(PXR), and N-methylcytisine, an alkaloid constituent of S. flavescens,
was identified to be a potent PXR activator [10]. Taken together,
these findings suggest that there may be potential herb-drug
interaction when S. flavescens is used, especially in conditions
involving the prescription of multiple medicinal compounds, for
example human immunodeficiency virus (HIV) infection and
acquired immune deficiency syndrome (AIDS).
Indinavir is a potent and specific protease inhibitor (PI) which
has long been used as a component of the highly active
antiretroviral therapy (HAART) for the treatment of HIV/AIDS.
Although new drugs have recently been developed, indinavir
remains a popular choice in many developing countries. The
metabolism of indinavir has been extensively studied in human,
rats, dogs, and monkeys [11–14]. It is metabolized predominantly
via CYP3A and is also a substrate of P-glycoprotein (P-gp), an
efflux transporter that can limit the oral absorption of indinavir.
Consequently, co-administration of foods, drugs or dietary
supplements with influences on CYP3A and/or P-gp may affect
the pharmacokinetics of indinavir, causing undesirable toxicity
and/or diminishment of drug efficacy. Piscitelli et al. [15] reported
that the plasma levels of indinavir were reduced in healthy
volunteers after co-administration of St. John’s wort. A recent
study in rats confirmed that St. John’s wort decreased plasma
indinavir concentrations, and the interaction was attributed to the
induction of indinavir metabolism in liver and intestine [16]. The
therapeutic range of PIs is relatively narrow, and the antiretroviral
activity correlates closely to their plasma concentrations [17]. Low
plasma concentrations of PIs can cause viral resistance and
treatment failure [18], and conversely, elevated plasma concen-
trations may enhance drug toxicity [19].
Given the shared transmission routes, HIV patients are
vulnerable to multiple viral co-infections such as that of hepatitis
B virus (HBV) and hepatitis C virus (HCV) [20,21]. Matrine and
oxymatrine, two major components of S. flavescens, are widely used
in the treatment of chronic viral hepatitis in China [22,23].
Sophora-derived products such as the Marine Capsule are often
taken by HBV- or HCV-coinfected HIV patients while they are
receiving indinavir. Against these backgrounds, the current study
aims to establish an animal model to evaluate potential herb-drug
interaction between Sophora flavescens and indinavir, and to explore
the possible underlining mechanisms. To mimic the situations in
clinical practice, rats were orally administered with indinavir and
S. flavescens extract, or its ingredients, concomitantly for seven
consecutive days. Plasma concentration profile and urinary and
faecal excretion of indinavir were then determined. The possible
involvement of P-gp and CYP3A in this interaction was examined
by measuring the intestinal and hepatic mRNA/protein levels and
enzyme activity.
Materials and Methods
Preparation of Sophora Extract
Dried roots of Sophora flavescens (500 g, Batch Number: 001110),
provided by Zhixin Pharmaceutical Company (Guangdong,
China), were authenticated by Miss Yuying Zong using pharma-
copoeial procedures (Chinese Pharmacopoeia, 2010) [1]. Voucher
samples (HHSF-SF-001) have been deposited at the School of
Chinese Medicine, the Chinese University of Hong Kong. The
pulverized materials were soaked in 70% ethanol (4 L) for 30 min
at room temperature, followed by boiling three times (1 h each) in
4 L, 3 L and 3 L of 70% ethanol, successively. The combined
extract was filtered and concentrated by rotary evaporation under
reduced pressure. Finally, the concentrate was freeze-dried to
obtain a powder (31.6% yield from the dried plant material),
which contained approximately 11.1% oxymatrine (by HPLC-UV
determination at 220 nm). Part of the Sophora extract powder (c.a.
50 g) was suspended in hot water (200 mL) and partitioned with
equal volume of ethyl acetate (EA) for three times. The organic
layers were combined, evaporated under reduced pressure, and
freeze-dried. The yield of EA fraction was 13% from Sophora total
extract and the oxymatrine content in the EA fraction was less
than 0.02%. The dried powder was stored in a desiccator at room
temperature until use. Marine Capsule (containing .95%
oxymatrine) was purchased from Chia-Tai Tianqing Pharmacy
Co. Ltd. (Jiangsu, China).
Animals
Male Wistar rats (230–260 g) were bred and housed by the
Laboratory Animal Services Centre of the Chinese University of
Hong Kong. All experiments were performed with approval from
the Animal Research Ethics Committee of the Chinese University
of Hong Kong. A License to Conduct Experiments was obtained
from the Department of Health, the Hong Kong Special
Administrative Region Government [Ref No: (09-515) in DH/
HA&P/8/2/1 Pt.10]. The animals were kept in a temperature-
controlled room (2362uC) with a 12-h light-dark cycle, with free
access to food and water.
Pharmacokinetic Studies of Indinavir
Thirty rats were randomly designated as vehicle control, low-
dose and high-dose Sophora treatment groups (ten rats in each
group). A separate experiment was performed using eighteen rats
designated as vehicle control, oxymatrine capsule and Sophora EA
fraction groups (six rats in each group). The Sophora extract and EA
fraction powders were homogenized in 1.5% Tween 80 with a
mortar and pestle. Indinavir from CRIXIVANH capsule (Merck &
CO. Inc., Whitehouse Station, NJ, USA) was dissolved in 50 mM
citric acid, and the oxymatrine capsule contents were dissolved in
distilled water. Rats were gavaged with 1.5% Tween 80 (vehicle),
Sophora extract (0.158 g/kg or 0.63 g/kg), oxymatrine capsule
(45 mg/kg of oxymatrine equivalent), or Sophora EA fraction
(82 mg/kg), respectively. To avoid possible physiochemical
influence on indinavir absorption, indinavir (40 mg/kg) was given
to all animals by gavage an hour later. The treatments were given
twice a day (9 a.m. and 7 p.m.) for 7 consecutive days. The dosages
were designed on the basis of clinical doses in human. The daily
dose of S. flavescens recommended by the Chinese Pharmacopoeia
is 4.5–9 g of raw herb per day [1]. The ‘‘Kushen Pian’’ (literally
meaning ‘‘Sophora tablet’’), a Sophora-derived formulated product
for the treatment of eczema, is used at a dose equivalent to 12–
18 g of raw herb per day [24]. Taking the low and high ends of
these dose ranges, and using a conversion based on the body-
surface-area ratio between rats and human, an animal dose range
of 0.45–1.8 g/kg/day (raw herb equivalent) was estimated for
experimental rats. Subsequently, two dose levels, 0.316 and
1.26 g/kg/day, were selected for use in the present study to
represent the low- and high-dose levels.
To study the excretion of indinavir, the rats were placed in
individual metabolic cages after the second daily treatment (8
p.m.) on the sixth dosing day, and urine and faeces samples were
collected until 8 p.m. on day 7. On the experimental day (day 8),
animals were treated with the last dose of vehicle or Sophora
preparations, and thereafter indinavir. Under anesthetization with
isoflurane, blood samples (0.3 mL) were collected before indinavir
dosing and at 0.25, 0.5, 1, 1.5, 2, 3, 4 and 5 h after dosing by
orbital bleeding via heparinized capillary tubes. Plasma was
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frozen at 280uC prior to analysis. After the last sampling at 5 h,
rats were sacrificed by cervical dislocation. Organ tissues,
including liver and intestine, were isolated, rinsed with saline,
blotted dried, snap-frozen in liquid nitrogen, and stored at 280uC
until use.
Measurement of Hepatic and Intestinal mRNA
The amounts of mRNA encoding CYP3A1, CYP3A2 and P-gp
(mdr1a and mdr1b) in the intestine and liver were quantified by
real-time PCR. The tissues (,100 mg) were homogenized in 1 mL
Trizol reagents (Invitrogen, Carlsbad, CA, USA). Total RNA was
extracted using chloroform and isopropanol. The RNA was
quantified by the standard OD260 method. The OD260/OD280
ratio for each RNA sample ranged from 1.8 to 2.2. Subsequently,
RNA was converted to cDNA using high-capacity cDNA reverse
transcription kit (Applied Biosystems, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Taqman assays were
performed for the quantification of mRNA in an ABI step-one real
time PCR system (Applied Biosystems, , Carlsbad, CA, USA).
Specific primers for CYP3A1, CYP3A2, mdr1a, mdr1b and the
housekeeping gene b-actin were purchased from Applied Biosys-
tems (product codes: Rn01412959_g1, Rn00756461_m1,
Rn01639253_m1 and Rn00561753_m1, respectively). The rela-
tive mRNA levels were calculated by the 2
2DDCT method [25].
Measurement of Intestinal and Hepatic CYP3A and P-gp
Protein Expression
Intestinal brush border membrane (BBM), intestinal mucosa
homogenate and liver microsomes were used for protein analysis.
The frozen small intestine (ileum and jejunum) was cut open on a
glass plate. Intestinal mucosa was collected by scraping and
homogenized with a glass tube homogenizer (striking with a loose
fitting pestle) in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 1% v/v NP-40, 0.5% sodium deoxycholate, and 1% 1006
protease inhibitor mixture (GE Healthcare, Waukesha, WI, USA).
The homogenate was divided to two portions. One portion was
allowed to settle on ice for 30 min after homogenization, and then
centrifuged at 10,0006 g for 20 min. The resulting supernatant
was collected for the analysis of intestinal CYP3A. The other
portion was used for the preparation of intestinal BBM according
to a modified calcium precipitation method [26]. CaCl2 was added
to a final concentration of 10 mM to the homogenate. After
settling on ice for 30 min, the homogenate was centrifuged at
3,0006 g for 15 min, and the resulting supernatant was further
centrifuged at 24,0006g for 40 min. The pellet was resuspended
in lysis buffer for the analysis of intestinal P-gp.
Liver microsomes were prepared by a differential centrifugation
method. Briefly, 5 g of frozen liver was homogenized in 0.1 M
potassium phosphate buffer (pH 7.4; 10 mL), containing 3.3 mM
MgCl2, with a high-speed homogenizer. The homogenates were
centrifuged at 9,000 g for 30 min, and the resulting supernatants
were further centrifuged at 100,0006g for 60 min. The pellet was
rinsed with potassium phosphate buffer, spinned down at
100,0006 g and resuspended in buffer (0.1 M potassium
phosphate, pH 7.4, 3.3 mM MgCl2 and 250 mM sucrose) for
the analysis of hepatic CYP3A and P-gp.
Protein contents were quantified by the Bio-Rad (Hercules, CA,
USA) protein assay kit. Samples of intestinal BBM (80 mg for P-
gp), intestinal mucosa supernatant (20 mg for CYP3A), or liver
microsome (10 mg for CYP3A and 80 mg for P-gp) were resolved
in 8% or 12% SDS-polyacrylamide gel (Mini-PROTEIN 3
System, Bio-Rad) and transferred to polyvinylidene difluoride
membranes, which were blocked for 1.5 h in a buffer containing
5% nonfat milk, 150 mM NaCl, 15 mM Tris (pH 7.6), and 1 mM
EDTA. The membranes were then probed with anti-P-gp
monoclonal antibody C219 (1:1000, EMD Chemicals, Gibbstown,
NJ, USA), specific anti-CYP3A1 or anti-CYP3A2 polyclonal
antibody (1:4000, Millipore, Billerica, MA, USA), or anti-ERp29
polyclonal antibody as control (1:5000, Thermo Scientific,
Waltham, MA, USA) in Tris-buffered saline containing 0.05%
Tween 20 at 4uC overnight. After washing three times with Tris-
buffered saline (10 min each), the membranes were incubated with
horseradish peroxidase-conjugated secondary antibody (1:5000,
Cell Signaling Technology, Danvers, MA, USA) for 1 h at room
temperature. After the blots were washed three times with Tris-
buffered saline, the immunoreactive bands were detected with the
enhancing chemiluminescence plus detection system (Amersham
Pharmacia Biotech Inc., Piscataway, NJ, USA), and visualized on
X-ray films. Band intensity was then scanned and quantified using
the Gel-Pro Analyzer 4.0 software (Media Cybernetics, Bethesda,
MD, USA). The P-gp, CYP3A1 and CYP3A2 intensities were
normalized to that of ERp29.
CYP3A Activity Assay
The hepatic CYP3A activity was measured by a luminescent
assay (P450-Glo) according to the manufacturer’s instructions
(Promega Corporation, Madison, WI, USA). Briefly, rat liver
microsomes were prepared using differential centrifugation
described above. The CYP3A catalytic reaction was performed
in 200 mM potassium phosphate buffer solution (pH 7.4). A
reaction mixture, containing microsomal protein (0.8 mg/mL)
and Luciferin-BE substrate (50 mM), was pre-incubated at room
temperature for 10 min. The reaction was initiated by adding
NADPH-regenerating system (b-NADP
+, glucose-6-phosphate
and glucose-6-phosphate dehydrogenase). After 20-min incuba-
tion, Luciferin detection reagent was added and allowed for 20-
min incubation. Luminescence, which was in proportion to
CYP3A activity, was measured by a luminometer. The relative
CYP3A activity was expressed as the fold over control.
Analytical Methods
Concentrations of indinavir in the biological specimens were
determined by HPLC-MS according to previous reports [27,28]
with minor modifications. Midazolam was used as the internal
standard. Plasma and urine samples (100 mL) were alkalized by
50 mM NaOH solution after addition of midazolam (20 mL,
50 mg/mL), and then extracted with ethyl acetate (1 mL) for
15 min. The organic layers were transferred to glass tubes, and
dried under nitrogen at 45uC. The residues were reconstituted
with 200 mL of methanol-water (v/v, 1:1) solution. The faeces
were homogenized in about 4-fold volume of distilled water. The
homogenates were extracted with equal volume of acetonitrile.
After centrifugation, 1 mL of the supernatant was transferred to a
glass tube, and was subsequently subjected to addition of
midazolam, alkalization, extraction with ethyl acetate, drying
and reconstitution. All reconstituted samples (60 mL) were
separated on a Prevail C18 column (250 mm64.6 mm I.D.,
5 mm, Alltech) by an Agilent 1100 HPLC system (Agilent
Technologies, Santa Clara, CA, USA). The flow rate was
0.8 mL/min. The mobile phase consisted of 0.1% trifluoroacetic
acid water (A) and acetonitrile (B) programmed to a gradient
elution of 20–37% B at 0–13 min. The effluent was introduced to
APCI-MS (Agilent 1100 series LC/MSD Trap SL system, Santa
Clara, CA, USA) with positive detection mode. The scan range
was set from m/z 150–900 and the target mass was m/z 470. MS
conditions were optimized as follows: nebulizer (N2), 50 psi; dry
gas (N2), 5 L/min; drying gas temperature, 325uC; compound
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grams at m/z 614 (indinavir) and m/z 326 (midazolam) were used
for quantification (Figure S1). Quantification of indinavir was
performed on six levels of standards in blank plasma or faeces
homogenate. The calibration curves showed good linear correla-
tion (r
2$0.99) between peak area ratio (indinavir over midazolam)
and concentrations. Intra- and inter-day precision of the method
was within the acceptable limits with R.S.D.,10%. Samples were
stable for 72 h at room temperature (R.S.D.,5%). The recovery
of the analyte ranged from 80% to 90%.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic parameters of indinavir were determined by a
noncompartmental pharmacokinetic model using the PK Solu-
tions 2.0.2 software (Summit Research Services, Ashland, OH,
USA). The area under the plasma concentration-time curves from
zero to infinity (AUC0-‘) was calculated by the trapezoidal rules.
Clearance (CL) was calculated by the equation (F6Dose)/AUC0-
‘, where F is the fraction of dose available in the systemic
circulation. Peak plasma concentration (Cmax) and the time when
it occurred (Tmax) were derived directly from the curves. Statistical
differences were determined by unpaired Student’s t test or one-
way analysis of variance (one-way ANOVA) followed by Dunnett’s
post test. All tests were two-tailed and the significance was set at
P,0.05.
Results
Effect of Sophora flavescens on Plasma Indinavir
Concentrations
The effect of Sophora extract on the multiple-dose pharmacoki-
netics of indinavir was assessed by measuring the plasma
concentrations. The plasma concentration profiles of indinavir
on the experiment day (day 8), with or without Sophora co-
treatment, are shown in Figure 1(A). At time zero, plasma
indinavir concentration was detectable, but was much lower than
the limit of quantification (50 ng/mL). The pharmacokinetic
parameters of the control and treatment groups are shown in
Table 1. Maximum plasma concentration (Cmax) in vehicle-treated
rats was 11.54 mg/mL, while that in the Sophora-treated rats
decreased dose-dependently by 38% (P,0.01) and 78% (P,0.001)
in the low-dose (0.316 g/kg per day) and high-dose groups
(1.26 g/kg per day), respectively. The AUC0-‘ of indinavir in
Sophora-treated rats decreased as well, showing 55% (P,0.001) and
83% (P,0.001) reduction in the respective treatment group.
Meanwhile, Sophora-treated rats displayed significantly higher CL/
F value than the control, with dose-dependent increases by 2.4-
fold (P,0.001) and 7.4-fold (P,0.001) in the low- and high-dose
groups, respectively. On the other hand, the Tmax value was not
significantly altered after Sophora treatment.
In a separate experiment, the effects of oxymatrine capsule
(containing .95% oxymatrine) and Sophora EA fraction on
indinavir pharmacokinetics were studied. As shown in
Figure 1(B), plasma indinavir concentrations were reduced when
co-administered with the oxymatrine capsule (equivalent to
90 mg/kg/day of oxymatrine). Compared to the control, the
AUC0-‘ and Cmax values in the oxymatrine-treated rats were
decreased by 61% (P,0.001) and 54% (P,0.001), respectively
(Table 1). Oxymatrine capsule treatment also increased the CL/F
value by 2.2-fold (P=0.017). In contrast, treatment of rats with
Sophora EA fraction, at a dose (0.164 g/kg/day) equivalent to
1.26 g/kg/day of Sophora total extract, had no effect on indinavir
pharmacokinetics, not affecting the AUC0-‘,C max, Tmax or CL/F
values. An HPLC-MS analysis revealed that prenylated flavonoids
were present in the Sophora EA fraction, while the other fractions
contained quinolizidine alkaloids including matrine and oxyma-
trine (Figure S2).
Effect of Sophora Extract on Indinavir Excretion
Urine and faeces were collected from day 6 to day 7 (for 24 h) to
examine the effect of Sophora extract on indinavir excretion.
Figure 1. Time course of the plasma concentration of indinavir.
Animals received oral administration of indinavir (40 mg/kg) together
with (A) 1.5% Tween 80 (vehicle), 70% ethanol extract of Sophora
flavescens (0.158 g/kg and 0.63 g/kg), (B) Oxymatrine capsule (45 mg/
kg of oxymatrine equivalent), or ethyl acetate (EA) fraction of Sophora
extract (0.082 g/kg), twice a day for 7 days, respectively. On the
experimental day (day 8), animals were pretreated with corresponding
vehicle or tested drugs at 1 h prior to the last dose of indinavir (40 mg/
kg) given to all rats for pharmacokinetic study. Values are expressed as
mean 6 S.E.M. for each data point (n=6–9).
doi:10.1371/journal.pone.0031312.g001
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dose-dependently with up to 2-fold increase in high-dose group as
compared to the control, which reflects the diuretic effect of S.
flavescens. However, the fractions of indinavir found in the urine
relative to the doses given to animals was, respectively, reduced by
63% and 71% in low-dose and high-dose groups (P,0.001,
Figure 2(C)). There was no significant alteration in faecal outputs
after Sophora treatment (Figure 2(B)), whereas the fraction of
indinavir found in the faeces (relative to dose) from rats treated
with high Sophora dose was 1.7-fold higher than that in the control
rats (P=0.021, Figure 2(D)).
Effect of Sophora Extract on CYP3A Expression in the
Intestine and Liver
To determine the effect of 7-day co-administration of Sophora
extract on the expression of intestinal and hepatic CYP3A, mRNA
and protein levels were measured by real-time PCR and Western
blotting analysis, respectively. The mRNA levels of b-actin
indicated by CT values did not change significantly between
control group and treatment groups, thus it was used as the
endogenous control for calculating relative mRNA expression.
Specific primers for CYP3A1 or CYP3A2 were used for the
initiation of polymerase chain reaction. In the small intestine,
mRNA level of CYP3A1 was found to be higher than that of
CYP3A2, as evidenced by the lower CT value for CYP3A1 (data
not shown). Figure 3(A) shows a dose-dependent increase in the
intestinal mRNA levels of CYP3A1 in Sophora-treated rats, with
2.4-fold (P=0.053) and 3.4-fold (P=0.027) enhancement in the
low- and high-dose groups, respectively. In contrast, Sophora
treatment appeared to decrease the intestinal mRNA level of
CYP3A2; and dosing with 1.26 g/kg/day Sophora extract showed a
54% reduction (P=0.033, Figure 3(B)). In liver, mRNA levels of
CYP3A1 and CYP3A2 were comparable (data not shown).
Compared to the control, treatment with 1.26 g/kg/day Sophora
extract significantly increased the hepatic mRNA levels of
CYP3A1 by 96% (P=0.006, Figure 3(A)). On the other hand,
the hepatic mRNA level of CYP3A2 was not significantly
influenced by Sophora treatment, although there was a slight
decline in the high-dose group (P=0.101).
The CYP3A1 and CYP3A2 antibodies specifically recognized a
protein band of 58 kDa and 53 kDa, respectively. As shown in
Figure 4(B), both CYP3A1 and CYP3A2 could be detected in the
liver samples, while in the intestinal mucosa, only CYP3A1 could be
detected. In contrast to the mRNA results, treatment of Sophora
extract didnotaltertheproteinlevelsofCYP3A1or CYP3A2 inthe
small intestine and liver (Figure 4). This might be because the basal
level of CYP3A was already at such a high level that further increase
in mRNA would not lead to a significant change of protein level.
Effect of Sophora Extract on P-gp Expression in the
Intestine and Liver
Effects of Sophora treatment on the intestinal and hepatic P-gp, an
ATP-binding cassette (ABC) transporter also known as multidrug
resistance protein (MDR) 1, expressions were examined. Two specific
primers for the mdr1 gene subunits, mdr1a and mdr1b, were used for
the measurement of P-gp mRNA levels. Figure 3(C) shows that, when
compared to the control, Sophora treatment dose-dependently
increased the intestinal mRNA level of mdr1a, with 80% (P=0.073)
and 125% (P=0.003) enhancement in the low- and high-dose groups,
respectively.There was no significant difference in the mRNA levels of
mdr1b between the vehicle-treated and Sophora-treated rats (P.0.05,
Figure 3(D)).In the liver, the mRNA expression ofmdr1a waselevated
in the Sophora-treated rats, with 38% (P=0.098) and 75% (P=0.017)
increase in the low- and high-dose groups, respectively (Figure 3(C)).
Meanwhile, as shown in Figure 3(D), high-dose Sophora treatment led
to an increase in the hepatic mRNA level of mdr1b by 4.4-fold
compared to the control (P=0.002), while low-dose treatment did not
show significant effect (P.0.05).
Figure 5(B) shows that P-gp was detected in both intestinal BBM
and liver microsomes. Both intestinal and hepatic P-gp protein levels
were elevated in the Sophora-treated rats. Compared to the control,
low-dose Sophora treatment increased the intestinal and hepatic P-gp
levels by 150% (P=0.183) and 89% (P=0.032), respectively
(Figure 5(A)). The effects of high-dose treatment were even more
significant, showing 2-fold (P=0.034) and 2.7-fold (P,0.001)
enhancements in the intestine and liver respectively (Figure 5(A)).
Effect of Sophora Extract on Hepatic CYP3A Activity
The hepatic CYP3A activity was measured using a luminescent
assay. Figure 6 reveals that the CYP3A activity in the liver was up-
regulated after treatment with Sophora extract, showing 20%
(P=0.315) and 51% (P=0.024) enhancements in the low- and
high-dose groups, respectively.
Discussion
Clinical and experimental evidence of herb-drug interactions
have suggested that the combined use of herbs and prescribed
Table 1. Pharmacokinetic parameters of indinavir (40 mg/kg orally) after multiple dosage.
Vehicle control Sophora extract
Oxymatrine
(90 mg/kg/day)
EA fraction
(0.164 g/kg/day)
0.316 g/kg/day 1.26 g/kg/day
AUC0-‘ (mg?h/mL) 16.0760.99 7.2360.87*** 2.7860.61*** 5.2961.11*** 12.2761.31
Cmax (mg/mL) 11.5460.67 7.1760.69** 3.0961.08*** 4.9760.81*** 8.4160.86
Tmax (h) 0.5060.10 0.6260.12 0.5060.19 0.4260.12 0.6760.15
CL/F (mL/h/kg) 25706183 60476693*** 1895863513*** 956962302* 34596421
The rats received oral administration of indinavir (40 mg/kg) together with 1.5% Tween 80 (vehicle), Sophora extract (0.158 g/kg or 0.63 g/kg), Oxymatrine capsule
(45 mg/kg of oxymatrine equivalent), or ethyl acetate (EA) fraction of Sophora extract (0.082 g/kg), twice a day for 7 days, respectively. On the experimental day (day 8),
animals were pretreated with corresponding vehicle or tested drugs at 1 h prior to the last dose of indinavir given to all rats for pharmacokinetic study. Values are
expressed as mean 6 S.E.M. (n=6–9). Significance is indicated as
*P,0.05,
**P,0.01,
***P,0.001, compared to vehicle control.
doi:10.1371/journal.pone.0031312.t001
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toxicity [29]. This is particularly important for patients suffering
from chronic infections such as HIV/AIDS patients who are
dependent on life-long antiretroviral treatment. It has been
demonstrated that prolonged co-administration of health products,
such as milk thistle, St John’s wort and vitamin C supplements, will
lead to a decrease of plasma indinavir concentrations with AUC
reduction up to 57% [15,30,31]. For safety reason, it is thus
important to evaluate the potential pharmacokinetic interaction
between natural products and oral pharmaceutics in animals
before conducting studies in human. In this study, the interaction
between a herb, namely, S. flavescens and a commonly used
antitretroviral, as exemplified by indinavir, a PI, was investigated
in rats. Our findings demonstrated that co-administration of S.
flavescens extract and indinavir (7-day) significantly decreased the
plasma concentrations of the latter. In the Sophora-treated rats, the
amount of faecal indinavir increased, whereas the urinary
excretion markedly decreased. Biochemical studies suggested that
the interaction was associated with the induction of intestinal and
hepatic P-gp and CYP3A. To the best of our knowledge, this is the
first report to demonstrate the impact of S. flavascens on the
multiple-dose pharmacokinetics of indinavir.
When the Sophora extract was fractionated by partitioning with
organic solvents, an ethyl acetate-soluble (EA) fraction was
obtained. Treatment of rats with this Sophora EA fraction had no
effect on indinavir pharmacokinetics, suggesting that the constit-
uents of the EA fraction (mainly prenylated flavonoids) were
unlikely to have contributed to the pharmacokinetic interaction. It
is speculated that the herb-drug interaction may be mediated by
the alkaloidal components of the plant. Such a speculation was
supported by the observation that co-administration with oxyma-
trine capsule significantly decreased the plasma indinavir concen-
trations, with 61% reduction in AUC0-‘. Although other active
ingredients may be present in the extract, oxymatrine is definitely
an important component of S. flavascens associated with the
pharmacokinetic interaction with indinavir. Since the experimen-
tal dose of oxymatrine is equivalent to a human dose of 0.9 g/day,
the use of Marine capsule in HIV patients receiving indinavir
should be cautioned.
Metabolically indinavir is designated as a Class 2 drug (low
solubility/high permeability/extensive metabolism) [32]. The
compound is highly permeable across the epithelium, as suggested
by a rapid absorption rate (Tmax: 30–35 min) after oral admi-
nistration [12]. The Tmax value of indinavir determined in our
study, ranging from 30 to 37 min, was consistent with values
published in the literature. On the other hand, the bioavailability
of indinavir is largely limited by efflux through intestinal P-gp and
first-pass metabolism by CYP3A [14,33], with the reported oral
bioavailability in rats of 26%. In the present study, plasma
indinavir concentrations decreased after co-administration of
Sophora extract, resulting in a reduction of Cmax and AUC0-‘.
The decrease of Cmax suggested that S. flavescens could enhance
intestinal drug efflux and/or first-pass metabolism, thereby
reducing the portion of indinavir entering systemic circulation. A
Figure 2. Effect of Sophora extract on the output of urine and faeces, and on indinavir excreted via urine and faeces. (A) Urine output,
(B) Faeces output, (C) Indinavir excreted in urine, (D) Indinair excreted in faeces. The urine and faeces were collected from 8 p.m. on day 6 (after the
second daily treatment) to 8 p.m. on day 7 (before the second daily treatment). Values are expressed as mean 6 S.E.M. (n=8–9).
doi:10.1371/journal.pone.0031312.g002
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wort and indinavir [16], in which both intestinal and hepatic first-
pass metabolism contributed to the reduction of indinavir
bioavailability. Our findings also showed a dose-dependent
increase in the CL/F value of indinavir after Sophora treatment,
which can be interpreted as an enhancement of systemic
clearance, reduction of absorption, and/or induction of first-pass
metabolism. The contribution of each of these components to the
decrease of indinavir exposure by S. flavescens remains to be
characterized.
In our study urinary indinavir contents dropped in Sophora-
treated rats (24-h), when compared to the control. Since urinary
excretion of a drug correlates closely with its plasma concentra-
tion, this observation can reasonably be explained by the
remarkable reduction of plasma indinavir (AUC) after Sophora
treatment. On the other hand, the faecal indinavir content in
Sophora-treated rats was higher than that of the control. The
elevation was likely caused by the enhanced efflux of indinavir
through an induction of intestinal P-gp (see below). In addition,
since biliary excretion is also involved in the excretion of indinavir
[12], the role of biliary pathway in the pharmacokinetic
interaction remains to be investigated.
The CYP metabolic enzyme system and drug transporters are
known to be inducible and they are often involved in herb-drug
interactions [34]. Previous studies have established the pivotal
roles of P-gp and CYP3A in the absorption and metabolism of
indinavir [13,14]. Plasma indinavir exposure decreased after pre-
treatment with dexamethasone in rats, and the effect was
attributed to the intestinal and hepatic first-pass metabolism
through an induction of CYP3A and P-gp [33]. Our findings
showed that Sophora treatment could induce the mRNA expression
of CYP3A1 in the small intestine and liver, but had little effect on
CYP3A2. Similar results were reported using dexamethasone as
the ligand of pregnane X receptor (PXR) [35], which is a ligand-
activated transcriptional regulator for drug metabolism and plays a
dominant role in regulating CYP3A transcription [36]. Cell-based
experiments have suggested that S. flavescens could induce CYP3A4
mRNA expression via the activation of PXR, and N-methylcyti-
sine was identified as an active principle [10]. Thus, our
observation of elevated CYP3A1 mRNA levels by S. flavescens
might also be caused by PXR activation. Although protein
expressions of CYP3A1 and CYP3A2 in the intestine and liver
were not affected by Sophora treatment, hepatic CYP3A activity
appeared to be elevated after Sophora treatment, which was
consistent with the reported inductive effect of S. flavescens on
CYP3A [7,8]. The up-regulation of CYP3A activity enhanced
indinavir metabolism and hence facilitated drug elimination,
which can partially explain the decreased concentrations of
indinavir.
Another determining factor involved in the herb-drug interac-
tion is the P-gp. Indinavir is a known substrate of P-gp [14]. After
co-administration of Sophora extract, dose-dependent increases in
the intestinal and hepatic mRNA levels of P-gp were observed.
Although the regulation of P-gp was complex and variable among
tissues [35], the concurrent induction of CYP3A and P-gp in the
small intestine and liver has previously been reported [33,37].
Figure 3. Effect of Sophora extract on the intestinal and hepatic mRNA levels encoding CYP3A1, CYP3A2, mdr1a and mdr1b. (A)
CYP3A1, (B) CYP3A2, (C) mdr1a, (D) mdr1b. The mRNA contents were measured by real-time PCR and calculated as comparative levels over control
using the 2
2DDCT method (mean 6 S.E.M., n=7–9). Statistical significance is indicated as * P,0.05, ** P,0.01, compared to control.
doi:10.1371/journal.pone.0031312.g003
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(MDR1) transcription is regulated by two nuclear receptors, the
PXR and the constitutive androstane receptor (CAR) [38,39],
which are also transcription regulators for CYP3A. It is thus
speculated that the chemical ingredients in S. flavescens that can
induce CYP3A expression may also induce P-gp via the activation
of common transcription factors. The alteration of P-gp protein
levels after Sophora treatment was in consensus with the elevation of
mRNA contents. Since intestinal P-gp mediates drug efflux and
limits the bioavailability of its substrates, the induction of intestinal
P-gp by S. flavescens was likely contributory to the decrease of
plasma indinavir, as well as the increase of faecal indinavir. In
addition, interplay between P-gp and CYP3A have been
demonstrated [40,41]. By extruding the drug from the enterocytes
to intestinal lumen during absorption, intestinal P-gp can increase
the residence time for exposure to intestinal CYP3A, and
consequently enhance its metabolism. A previous study showed
that during the transport of indinavir in Caco-2 cells expressing
CYP3A4, P-gp efflux resulted in more metabolites produced from
indinavir [14]. Likewise, in our study, the increased level of
intestinal P-gp, acting with CYP3A, may further enhance the
intestinal first-pass metabolism of indinavir and lead to the
dramatic decrease of its plasma concentrations. On the other
hand, unlike intestinal P-gp, hepatic P-gp unlikely had significant
effect on hepatic metabolism of indinavir [33]. It is evident that P-
gp and CYP3A cannot fully account for the entire process of
indinavir absorption and metabolism, and there must be other
mediators that remain to be identified.
In the guidelines recommended by the Food and Drug
Administration (FDA) for industry to study drug-drug interaction,
in vitro CYP-based metabolism information should be obtained in
the early stage [42]. In fact, most pharmaceutical companies use
mass screening for potential CYP inhibitors by applying enzyme
inhibition kinetics studies (calculating IC50, Km, Vmax, and Ki
Figure 4. Effect of Sophora extract on the expression of intestinal and hepatic CYP3A1 and CYP3A2. (A) Statistical data analysis of
Western blotting results, (B) image of Western blotting results. CYP3A1 and CYP3A2 levels were measured respectively using the specific anti-rat
CYP3A1 and CYP3A2 antibodies. ERp29 was used as control for the normalization of CYP3A density. Bars represent mean 6 S.E.M. of fold relative to
the values in the control group (n=7–8). No significant difference in the expression of either intestinal or hepatic CYP3A was observed.
doi:10.1371/journal.pone.0031312.g004
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using human pooled liver microsome and specific CYP3A4
isoform showed that Sophora extract inhibited CYP3A4 activity,
and the EA fraction was the active fraction (IC50 of 5.0 mg/mL),
implying that the Sophora EA fraction might exert influence on the
pharmacokinetics of CYP3A substrate, such as indinavir. Howev-
er, further experiments showed that the interaction between EA
fraction (at highest dose of 0.328 g/kg) and indinavir was not
observed in vivo (data not shown). It’s thus concluded that the in
vitro CYP enzyme inhibitory effects of herbal extracts may not
necessarily carry significant impacts on the drugs’ pharmacoki-
netics in vivo. In studying the induction potentials, ex vivo approach
has been commonly used by measuring the CYP enzymes’
expression and activity (probe substrate method) in liver after long-
term (7 days or 14 days) administration of the herbal extract. A
number of herbal medicines have been demonstrated to show
inductive effects, including S. flavescens [7,44]. It is however still
uncertain if ex vivo effect could be directly extrapolated to in vivo
conditions. Furthermore, ex vivo method tends to neglect the
potential effects on the absorption of oral pharmaceuticals, such as
inhibition or induction of intestinal transporters. When the drug is
a dual substrate for CYP enzyme and transporter, such as
indinavir (CYP3A and P-gp substrates), ex vivo study might not fully
characterize the potential of herb-drug interactions involving the
interplay of CYP enzyme(s) and transporter(s). It is against these
backgrounds that the present pharmacokinetic study was concep-
tualized. Nevertheless, the underlying mechanisms of the interac-
tion revealed in this study are far from fully understood. The
potential role of gene regulation and the interplay between
CYP3A and P-gp are yet to be uncovered, and an in vitro cell-based
study can be useful for delineating underlying mechanism.
Moreover, studies using human subjects or human-derived
specimens remain to be conducted to illustrate the clinical
significance as species difference may be present.
In summary, an animal model for characterizing plasma
pharmacokinetics, excretion, and interaction mechanisms in
herb-drug interactions is presented. Concomitant administration
of S. flavescens or oxymatrine resulted in a remarkable reduction in
plasma indinavir concentrations in rats, while the Sophora ethyl
acetate fraction had no effect. The pharmacokinetic impact on
indinavir was, at least in part, attributed to the induction of
CYP3A and P-gp in the small intestine and liver, as well as the up-
regulation of CYP3A activity. In spite of the presence of
interspecies difference, the pharmacokinetic interaction demon-
strated in the animal model implies that significant clinical
consequence might occur during concomitant administration of
Figure 5. Effect of Sophora extract on the expression of intestinal and hepatic P-gp. (A) Statistical data analysis of Western blotting results,
(B) image of Western blotting results. P-gp levels were measured using the anti-rat C219 antibody as described under Materials and Methods. ERp29
was used as control for the normalization of P-gp density. Bars represent mean 6 S.E.M. of fold relative to the values in control group (n=7–8).
Statistical significance is indicated as * P,0.05, *** P,0.001, compared to control.
doi:10.1371/journal.pone.0031312.g005
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whom antiviral resistance might rapidly develop under sub-
optimal plasma indinavir concentrations. Therefore, patients
receiving indinavir might be cautioned against the intake of S.
flavescens extract or Sophora-derived products.
Supporting Information
Figure S1 HPLC-MS extracted ion chromatogram of
indinavir (m/z 614) and midazolam (I.S., m/z 326) in
rat plasma obtained at 2 h after oral administration of
indinavir (40 mg/kg). The mass spectra of indinavir and
midazolam are shown.
(TIF)
Figure S2 Chromatograms of Sophora extract and
fractions. LC-MS analysis indicates the presence of flavonoids
(area B) in the ethyl acetate fraction, whereas the water fraction
mainly contains alkaloids (area A); the butanol fraction contains
both flavonoids and alkaloids. Oxymatrine was identified by
comparison with a standard. Other ingredients were tentatively
identified by their LC-MS/MS characters.
(TIF)
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